Differentiating Between Abemaciclib and Ribociclib

Treatment selection between abemaciclib and ribociclib is explored for a patient with extensive nodal involvement. The faculty compare differences in trial populations, duration of therapy, safety profiles, and monitoring requirements. The discussion explains why abemaciclib is often favored in very high-risk, node-positive disease, particularly in light of overall survival data from monarchE. At the same time, the importance of shared decision-making and flexibility is emphasized, including the option to switch agents if toxicity limits tolerability. This segment provides a structured framework for selecting a CDK4/6 inhibitor in complex, high-risk cases.